JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
The content, articles and product information provided on this website are strictly educational and informational. They are intended to be used for in vitro research only. “In vitro” is a Latin phrase, “in glass,” that refers to research that is conducted outside of a living organism. Note, these products are not pharmaceuticals or medicines and have not been approved by the FDA for the diagnosis, treatment or prevention of any illnesses or disorders. These products are legally prohibited from human or animal consumption.
Albuterol is a research compound studied in cell-based assay formats for its selective beta-2 adrenergic receptor (beta-2 AR) Gs/cAMP pathway agonism. Published in vitro research characterises its molecular interactions, binding affinity profiles, and downstream pathway engagement in defined cell model systems under controlled laboratory conditions. While traditionally investigated in respiratory cell models, contemporary research applications have expanded to include diverse cellular platforms for studying adrenergic receptor pharmacology and intracellular signalling mechanisms.
Albuterol acts via selective beta-2 adrenergic receptor (beta-2 AR) Gs/cAMP pathway agonism. Competitive radioligand binding assays demonstrate high selectivity for beta-2 AR subtypes compared to beta-1 and beta-3 adrenergic receptors in transfected cell lines. Saturation binding studies reveal nanomolar binding affinity (Ki = 1.5-3.2 nM) to human beta-2 AR expressed in CHO cell models, with functional potency (EC50 = 0.8-2.1 nM) for cAMP accumulation assays.
Beta-2 AR activation by albuterol initiates Gs-protein coupling, leading to adenylyl cyclase stimulation and intracellular cAMP elevation. Time-course studies in HEK293 cell models expressing recombinant beta-2 AR demonstrate rapid onset kinetics, with maximal cAMP responses occurring within 5-15 minutes following compound addition. Protein kinase A (PKA) activation assays confirm downstream pathway engagement through CREB phosphorylation measurements.
HEK293 and CHO cell lines transfected with human beta-2 AR constructs provide standardised platforms for pharmacological characterisation. These systems enable precise control of receptor expression density and facilitate structure-activity relationship studies through site-directed mutagenesis approaches. Stable cell lines expressing FLAG-tagged or GFP-fused beta-2 AR variants support both biochemical and imaging-based assays for receptor trafficking studies.
Primary human bronchial epithelial cells (HBECs) cultured at air-liquid interface serve as physiologically relevant models for studying albuterol's effects on endogenous beta-2 AR populations. These systems maintain native receptor expression patterns and enable investigation of receptor desensitisation mechanisms through prolonged compound exposure protocols.
Albuterol-induced cAMP elevation can be quantified using competitive immunoassays or fluorescence polarisation techniques. Concentration-response curves typically yield Hill coefficients near unity, indicating simple receptor occupancy models. Phosphodiesterase inhibitors such as IBMX enhance signal magnitude and duration, facilitating detection in cell models with lower receptor expression.
PKA activation assays measure CREB phosphorylation at Ser133 through Western blot analysis or high-content imaging platforms. Calcium mobilisation studies using fluorescent indicators reveal potential cross-talk with other signalling pathways, particularly in cell models co-expressing multiple adrenergic receptor subtypes.
Time-resolved FRET assays monitor beta-arrestin recruitment to activated beta-2 AR, providing kinetic data on receptor desensitisation processes. These studies reveal biphasic kinetics with rapid initial recruitment (t1/2 = 2-5 minutes) followed by sustained association phases lasting several hours in cell culture conditions.
Fluorescence microscopy approaches track receptor trafficking following albuterol stimulation. Confocal imaging reveals clathrin-dependent endocytosis pathways, with receptor internalisation occurring within 15-30 minutes of agonist exposure in most cell model systems.
Recent studies investigate potential biased signalling properties of albuterol across different effector pathways. Comparative analysis of G-protein activation versus beta-arrestin recruitment suggests preferential coupling to cAMP generation over arrestin-mediated responses, though this selectivity varies among cell model systems and experimental conditions.
Albuterol represents a valuable pharmacological tool for investigating beta-2 adrenergic receptor function in diverse cell-based assay systems. Its well-characterised binding profile, selective receptor activation, and robust downstream signalling make it suitable for mechanistic studies ranging from basic receptor pharmacology to complex pathway analysis. Contemporary applications extend beyond traditional airway cell models to include heterologous expression systems, primary cell cultures, and specialised assay platforms for studying receptor regulation and signalling bias. These expanded research applications continue to provide insights into adrenergic receptor biology and support development of improved experimental approaches for GPCR research.
All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition.
Forgot password?
Country: United States (US-only registration)
All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
ElementSarms is a chemical supplier. ElementSarms is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. ElementSarms is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.